《新股》药捷安康通过上市聆讯 去年亏损2.75亿人币

阿斯达克财经
Jun 11, 2025

药捷安康通过港交所(00388.HK) 上市聆讯,将在上市。公司核心业务模式涉及自主开发、研究及商业化小分子药物,以解决肿瘤、炎症及心脏代谢疾病领域的大量医疗需求。招股书披露,公司是以临床需求为导向、处于注册临床阶段的生物制药公司,专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。自于2014年注册成立以来,已自主发现及开发一种核心产品Tinengotinib(TT00420)以及建立五种...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10